Prot # ANA598-505: A Phase 2, Randomized, Double-Blind Placebo-Controlled Trial of the Safety and Efficacy of ANA598 Administered with Pegylated Interferon and Ribavirin in Genotype 1 Patients with Chronic Hepatitis C Infection

Project: Research project

Project Details

Effective start/end date3/14/113/14/14


  • Duke Clinical Research Institute (ANA598-505 // ANA598-505)
  • Anadys Pharmaceuticals, Inc. (ANA598-505 // ANA598-505)